JEFFERSON CITY, Mo. (CN) - Elan Corp. will pay $101 million to states and the federal government to settle claims of off-label marketing of its anti-epileptic drug Zonegran. Elan also must pay a $102 million criminal fine.
The $101 million settlement will reimburse Medicaid and Medicare. Missouri Attorney General Chris Koster said Missouri will receive $1.7 million.
Elan encouraged pediatric neurologists to prescribe Zonegran, though it was not approved for patients younger than 16. It also pushed the drug to treat neuropathic pain, obesity, headaches and a variety of psychiatric conditions that were not approved by the Food and Drug Administration.
Elan will also pay a $102 million criminal fine and has pleaded guilty to a federal misdemeanor of misbranding Zonegran through improper promotions.
In a related settlement, Eisai Inc. agreed in principle to pay $11 million for its improper promotion of Zonegran after it acquired interests in the drug from Elan in April 2004.
Doctors can prescribe drugs for off-label uses, but drug companies are not allowed to push the drugs for that.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.
Additional Reads
-
For role in opioid crisis, drug exec sentenced to prison March 8, 2023 -
US approves Alzheimer's drug that modestly slows disease January 6, 2023
-
Walmart offers to pay $3.1 billion to settle opioid lawsuits November 15, 2022 -
Doctors say 'fossil fuel addiction' kills, starves millions October 25, 2022